Quarterly ResultNov 5, 2026, 09:41 AM
Lipocine Q3 Revenue Jumps to $2.3M; Net Loss Narrows; TLANDO Approved in Canada
AI Summary
Lipocine Inc. announced its financial and operational results for the third quarter ended September 30, 2026. The company reported a substantial increase in revenue to $2.3 million from $115,000 in the prior year's quarter, alongside a narrowed net loss of $0.7 million, or $0.08 per diluted share, compared to $3.2 million, or $0.59 per diluted share, in Q3 2025. The company also provided a corporate update, highlighting the initiation of the Phase 3 BLOOM study for LPCN 1154 (BRLIZIO™) for postpartum depression and regulatory approvals for TLANDO® in Canada and the UAE. Unrestricted cash reserves grew to $28.5 million.
Key Highlights
- Lipocine Inc. reported Q3 2026 revenue of $2.3 million, a significant increase from $115,000 in Q3 2025.
- Net loss for Q3 2026 narrowed to $0.7 million ($0.08/share) from $3.2 million ($0.59/share) in Q3 2025.
- Unrestricted cash increased to $28.5 million as of Nov 4, 2026, up from $21.5 million at Sep 30, 2026.
- Health Canada approved TLANDO® for testosterone replacement therapy in adult males.
- Pharmalink received product marketing authorization for TESTYRA® (TLANDO) in the UAE.
- Phase 3 BLOOM study for LPCN 1154 (BRLIZIO™) for Postpartum Depression initiated, designed to enroll 120 participants.
- Research and development expenses decreased to $2.1 million in Q3 2026 from $2.7 million in Q3 2025.
Price Impact
More from LPCN